Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab

作者：Joseph J. Eron, Paul Cook, Megha Mehrotra, Hailin Huang, Marina Caskey, Gordon E Crofoot, Linda Gorgos, Laurie A. VanderVeen, Yanan Zheng, Sean E Collins, Olayemi Osiyemi, Cynthia Brinson, Edwin DeJesus · 发表于：The Journal of Infectious Diseases · 年份：2025 · DOI：10.1093/infdis/jiaf159 · 被引用次数：9 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、Biological Research and Disease Studies

BACKGROUND: The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs. METHODS: This was a pilot study within a proof-of-concept phase 1b study. RESULTS: No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26. CONCLUSIONS: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.